# 21 U.S.C. 357 Qualification of drug development tools

21 U.S.C. 357 Qualification of drug development tools, “Qualification of drug development tools”, is a U.S. Code section of [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 357](https://ontology.bommaritollc.com/id/01a0f06c-ccf9-704b-8dfc-d48a00a01d04)
- `eli:cites`:
  - [5 U.S.C. 552 Public information; agency rules, opinions, orders, records, and proceedings](https://ontology.bommaritollc.com/id/01a0edf4-5b27-7466-a019-fef93b12cea0)
  - [18 U.S.C. 1905 Disclosure of confidential information generally](https://ontology.bommaritollc.com/id/01a0f06a-9b21-77e5-b0e9-4b07425345ef)
  - [20 U.S.C. 1001 General definition of institution of higher education](https://ontology.bommaritollc.com/id/01a0f06c-0fb4-7451-a666-0a2862bda4f3)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8)
  - [Subchapter I—Administration and Miscellaneous Provisions](https://ontology.bommaritollc.com/id/01a0f07c-d2a8-71a0-898c-d3e3cf9ebb25)
  - [42 U.S.C. 247d Public health emergencies](https://ontology.bommaritollc.com/id/01a0f07c-d961-7148-9e7e-f0bbd971a175)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec357](https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7a6fd3d099)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d155-73e8-a3f5-81e3ab56ee61)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d50-7301-a041-169638127958)
  - [evidence from https://www.govinfo.gov/link/uscode/21/357?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe28-74e1-90ae-3525de185b76)
- `schema:isPartOf`: [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)
- `schema:legislationIdentifier`: 21 U.S.C. 357
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Qualification of drug development tools
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/357?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/357?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 357 Qualification of drug development tools

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/357?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec357) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (5; `eli:cites`):
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 379j-41 Definitions](https://ontology.bommaritollc.com/id/01a0f06c-cdab-70fd-bd75-579b5d1e1ff6)
  - [21 U.S.C. 379r National uniformity for nonprescription drugs](https://ontology.bommaritollc.com/id/01a0f06c-cdec-72c0-80d7-6b9561d8b5c6)
- Rules made under it (2; `eli:based_on`):
  - [21 CFR Part 208—Medication Guides for prescription drug products](https://ontology.bommaritollc.com/id/01a0f094-b83d-715a-a06f-19ec5ee04f89)
  - [21 CFR Part 530—Extralabel drug use in animals](https://ontology.bommaritollc.com/id/01a0f094-b877-7254-a31c-7add44bad47e)
- Amended by (1; `eli:amends`):
  - [Pub. L. 116-22](https://ontology.bommaritollc.com/id/01a0f06c-d323-74cf-ad3a-fa8f236ced10)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 114-255](https://ontology.bommaritollc.com/id/01a0ee1d-96d5-7151-84b6-b5e19f0e00ec)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11)
Cite as: 21 U.S.C. 357 Qualification of drug development tools. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
